• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

滤泡性甲状腺癌死亡的危险因素:系统评价和荟萃分析。

Risk factors for death of follicular thyroid carcinoma: a systematic review and meta-analysis.

机构信息

Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province, 110001, China.

出版信息

Endocrine. 2023 Dec;82(3):457-466. doi: 10.1007/s12020-023-03466-9. Epub 2023 Oct 7.

DOI:10.1007/s12020-023-03466-9
PMID:37804444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10618390/
Abstract

BACKGROUND

There are conflicting reports on the factors that increase the likelihood of patients dying from follicular thyroid carcinoma (FTC). Therefore, it is critical to identify risk factors of patients with FTC. This study aimed to identify the factors that increase the risk of death of patients with FTC and help clinicians make better treatment and follow-up decisions.

METHODS

A systematic literature review was conducted in PubMed and Web of Science databases for relevant studies published before January 31, 2023. Their reference lists were also analyzed. Two reviewers extracted data and evaluated the quality of eligible studies independently. Studies on patients who had open thyroidectomy procedures with or without neck dissection were included in this review. The RevMan 5.3 software was used to analyze the data.

RESULTS

This meta-analysis included thirteen studies with a total of 2075 patients. The following variables were associated with an increased risk of death in FTC patients: age > 45 years, male, tumor diameter > 4 cm, multifocality, extrathyroidal extension (ETE), widely invasive (WI), cervical lymph node metastasis (CLNM), distant metastases (DM) and non-radical resection tumor. Lobectomy and no radioactive iodine (RAI) treatment was not associated with the death of FTC patients.

CONCLUSION

Clinicians should pay closer attention to the following significant risk factors associated with the death of FTC patients: age (> 45), male, multifocality, tumor diameter > 4 cm, ETE, WI, non-radical resection tumor, CLNM, and DM. Individualized initial treatment and close follow-up are needed FTC patients who have these risk factors.

摘要

背景

关于增加滤泡状甲状腺癌(FTC)患者死亡风险的因素存在相互矛盾的报告。因此,确定 FTC 患者的风险因素至关重要。本研究旨在确定增加 FTC 患者死亡风险的因素,帮助临床医生做出更好的治疗和随访决策。

方法

在 PubMed 和 Web of Science 数据库中进行了系统的文献回顾,以检索截至 2023 年 1 月 31 日发表的相关研究。还分析了它们的参考文献列表。两位审查员独立提取数据并评估合格研究的质量。本综述纳入了接受甲状腺切除术(伴或不伴颈部清扫术)的患者的研究。使用 RevMan 5.3 软件分析数据。

结果

本荟萃分析共纳入 13 项研究,共计 2075 例患者。以下变量与 FTC 患者死亡风险增加相关:年龄>45 岁、男性、肿瘤直径>4cm、多灶性、甲状腺外侵犯(ETE)、广泛浸润(WI)、颈淋巴结转移(CLNM)、远处转移(DM)和非根治性切除肿瘤。甲状腺叶切除术和无放射性碘(RAI)治疗与 FTC 患者的死亡无关。

结论

临床医生应更加关注与 FTC 患者死亡相关的以下显著风险因素:年龄(>45 岁)、男性、多灶性、肿瘤直径>4cm、ETE、WI、非根治性切除肿瘤、CLNM 和 DM。对于具有这些风险因素的 FTC 患者,需要个体化的初始治疗和密切随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/62554955cce8/12020_2023_3466_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/8b547bcbb351/12020_2023_3466_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/f06a4089aee1/12020_2023_3466_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/d389eafd62c5/12020_2023_3466_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/dae2ba2245cb/12020_2023_3466_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/62554955cce8/12020_2023_3466_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/8b547bcbb351/12020_2023_3466_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/f06a4089aee1/12020_2023_3466_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/d389eafd62c5/12020_2023_3466_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/dae2ba2245cb/12020_2023_3466_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34ea/10618390/62554955cce8/12020_2023_3466_Fig5_HTML.jpg

相似文献

1
Risk factors for death of follicular thyroid carcinoma: a systematic review and meta-analysis.滤泡性甲状腺癌死亡的危险因素:系统评价和荟萃分析。
Endocrine. 2023 Dec;82(3):457-466. doi: 10.1007/s12020-023-03466-9. Epub 2023 Oct 7.
2
Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.甲状腺髓样癌中央区或侧颈部淋巴结转移的危险因素:系统评价和荟萃分析。
Eur Arch Otorhinolaryngol. 2024 Feb;281(2):547-561. doi: 10.1007/s00405-023-08249-6. Epub 2023 Oct 6.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
The risk of central nodal metastasis based on prognostic factors of the differentiated thyroid carcinoma: a systematic review and meta-analysis study.基于分化型甲状腺癌预后因素的中央区淋巴结转移风险:一项系统评价和荟萃分析研究。
Eur Arch Otorhinolaryngol. 2023 Jun;280(6):2675-2686. doi: 10.1007/s00405-023-07863-8. Epub 2023 Feb 10.
5
Follicular thyroid carcinoma metastasis to the facial skeleton: a systematic review.滤泡状甲状腺癌转移至面骨:一项系统综述
BMC Cancer. 2017 Mar 28;17(1):225. doi: 10.1186/s12885-017-3199-3.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
10
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.

引用本文的文献

1
The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.分化型甲状腺癌的初始风险分层系统:2024年韩国甲状腺协会指南的关键更新
Endocrinol Metab (Seoul). 2025 Jun;40(3):357-384. doi: 10.3803/EnM.2025.2465. Epub 2025 Jun 24.
2
A protein-based classifier for differentiating follicular thyroid adenoma and carcinoma.一种用于区分滤泡性甲状腺腺瘤和癌的基于蛋白质的分类器。
EMBO Mol Med. 2025 May 29. doi: 10.1038/s44321-025-00242-2.
3
[Update on follicular thyroid cancer-What is relevant for surgeons?].

本文引用的文献

1
Risk Factors and Prognosis for Metastatic Follicular Thyroid Cancer.滤泡性甲状腺癌转移的风险因素和预后。
Front Endocrinol (Lausanne). 2022 Mar 1;13:791826. doi: 10.3389/fendo.2022.791826. eCollection 2022.
2
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
3
Association of total cholesterol and atherosclerotic cardiovascular disease in patients with follicular thyroid cancer: A real-world study from Chinese populations.
[滤泡性甲状腺癌的最新进展——对外科医生有何重要意义?]
Chirurgie (Heidelb). 2025 Mar 27. doi: 10.1007/s00104-025-02276-1.
4
Prognostic impact of fibrosclerotic changes in non-papillary, non-anaplastic, follicular cell-derived thyroid carcinomas.非乳头状、非间变性、滤泡细胞源性甲状腺癌中纤维硬化性改变的预后影响
Virchows Arch. 2025 Jan 23. doi: 10.1007/s00428-025-04028-2.
5
Prognostic Factors for Cancer-Specific Survival and Disease-Free Interval in 130 Patients with Follicular Thyroid Carcinoma: Single Institution Experience.130例滤泡性甲状腺癌患者的癌症特异性生存和无病生存期的预后因素:单机构经验
Diagnostics (Basel). 2024 Dec 14;14(24):2817. doi: 10.3390/diagnostics14242817.
6
Development and validation of machine learning models for predicting lung metastasis risk in differentiated thyroid cancer based on two databases.基于两个数据库的预测分化型甲状腺癌肺转移风险的机器学习模型的开发与验证
Gland Surg. 2024 Nov 30;13(11):2174-2188. doi: 10.21037/gs-24-481. Epub 2024 Nov 26.
7
Diagnostic value of an interpretable machine learning model based on clinical ultrasound features for follicular thyroid carcinoma.基于临床超声特征的可解释机器学习模型对甲状腺滤泡癌的诊断价值
Quant Imaging Med Surg. 2024 Sep 1;14(9):6311-6324. doi: 10.21037/qims-24-601. Epub 2024 Aug 20.
8
Advances in the Diagnosis and Treatment of Follicular Thyroid Carcinoma: A Comprehensive Review.滤泡性甲状腺癌的诊断与治疗进展:综述
Cureus. 2024 Aug 5;16(8):e66186. doi: 10.7759/cureus.66186. eCollection 2024 Aug.
9
Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.基于术前、术中和术后发现的乳头状和滤泡状癌的预后因素。
Eur Thyroid J. 2024 Oct 4;13(5). doi: 10.1530/ETJ-24-0196. Print 2024 Oct 1.
滤泡性甲状腺癌患者总胆固醇与动脉粥样硬化性心血管疾病的相关性:来自中国人群的真实世界研究。
Medicine (Baltimore). 2021 Oct 1;100(39):e27310. doi: 10.1097/MD.0000000000027310.
4
Follicular Thyroid Carcinoma in a Developing Country: A 10-Year Retrospective Study.发展中国家的滤泡性甲状腺癌:一项10年回顾性研究
Cureus. 2021 Jul 23;13(7):e16594. doi: 10.7759/cureus.16594. eCollection 2021 Jul.
5
Prophylactic Central Neck Dissection in Well-differentiated Thyroid Cancer.分化型甲状腺癌预防性中央区淋巴结清扫术
Acta Clin Croat. 2020 Jun;59(Suppl 1):87-95. doi: 10.20471/acc.2020.59.s1.11.
6
Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review.滤泡性甲状腺癌复发的危险因素:系统评价。
Thyroid. 2021 Oct;31(10):1523-1530. doi: 10.1089/thy.2020.0921. Epub 2021 Jul 5.
7
Application of competing risk model in the prognostic prediction study of patients with follicular thyroid carcinoma.竞争风险模型在滤泡状甲状腺癌患者预后预测研究中的应用。
Updates Surg. 2022 Apr;74(2):735-746. doi: 10.1007/s13304-021-01103-6. Epub 2021 Jun 4.
8
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
9
Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic-based approach.甲状腺滤泡性良恶性肿瘤的手术指征及临床管理:基于算法的方法
Mol Clin Oncol. 2021 Feb;14(2):32. doi: 10.3892/mco.2020.2194. Epub 2020 Dec 17.
10
Outcomes for Minimally Invasive Follicular Thyroid Carcinoma in Relation to the Change in Age Stratification in the AJCC 8th Edition.第八版 AJCC 中年龄分层变化与微创滤泡状甲状腺癌预后的关系。
Ann Surg Oncol. 2021 Jul;28(7):3576-3583. doi: 10.1245/s10434-020-09397-3. Epub 2020 Nov 25.